Assessment of Early-detection Based on Liquid Biopsy in Lung Cancer (ASCEND-LUNG)
Detection of Early-stage Lung Cancer Based on Liquid Biopsy of Peripheral Blood: a Prospective Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Kezhong Chen, MD
- Phone Number: 08601088326650
- Email: chenkezhong@pkuph.edu.cn
Study Contact Backup
- Name: Fan Yang, MD
- Phone Number: 08601088326650
- Email: yangfan@pkuph.edu.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University People's Hospital
-
Contact:
- Chen Kezhong, M.D.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Signed informed consent
- Male or female, age equal to or greater than 40 years old and less than 75 years old
- Blood sample was collected before surgery for the detection of cfDNA methylation and other biomarkers
- Lung cancer patients diagnosed for the first time within 42 days before blood sampling without any anti-tumor treatment; or patients who are highly suspected of lung cancer through imaging evaluation or other routine clinical diagnosis and confirmed by tissue biopsy or surgical specimens within 42 days after blood sampling
- The subject has not received any local or systemic anti-tumor therapy before blood collection, including (not limited to) any surgery, local or systemic radiotherapy and chemotherapy, targeted therapy (including anti-angiogenesis), immunotherapy, cancer vaccines and hormone therapy, etc.
Exclusion Criteria:
- Unable to obtain sufficient and qualified blood samples
- Female subjects who are pregnant or breastfeeding
- Patients who have received organ transplantation or non-autologous bone marrow or stem cell transplantation
- Patients who have received blood transfusion within 7 days before blood sampling
- Patients who have received anti-infection treatment within 14 days before blood collection
- Patients who have receiving anti-tumor drugs for other diseases within 30 days before blood collection, such as methotrexate, cyclophosphamide, mercaptopurine, chlorambucil, tamoxifen, etc.
- Patients who suffered from other malignant tumors or multiple primary tumors at the same time
- Pathological confirmed benign lesions by tissue biopsy or surgery
- Insufficient sample for a confirmed pathological diagnosis
- Lung cancer patients with ground glass nodules on CT imaging.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of the multi-omics early-stage lung cancer diagnosis model
Time Frame: through study completion, an average of 1.5 year
|
Sensitivity and specificity of the multi-omics early-stage lung cancer diagnosis model
|
through study completion, an average of 1.5 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accuracy of diagnostic models established separately from multi-omics data
Time Frame: through study completion, an average of 1.5 year
|
Sensitivity and specificity models established separately from multi-omics data
|
through study completion, an average of 1.5 year
|
|
Relationship between multi-omics data
Time Frame: through study completion, an average of 1.5 year
|
Explore the relationship of features extracted from multi-omics data
|
through study completion, an average of 1.5 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Fan Yang, MD, Peking University People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PTHO2101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.